The drugmaker’s on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.
Source link
About The Author
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030